Clinicopathological features of colorectal cancer in patients under 40 years of age
- 164 Downloads
The aim was to identify the clinical factors and tumour characteristics that predict survival in patients younger than 40 years with colorectal adenocarcinoma.
Material and methods
Fifty-nine patients with colorectal cancer aged under 40 years were identified from a computer database, and their clinical variables were analysed. The factors predicting long-term survival were compared by both univariate and multivariate analysis.
The prevalence of positive family history of cancer was 27%, and predisposing factors were present in 31% of the patients. All patients underwent resective surgery, 76% radical and 24% palliative resection, and their 5-year survival was 59% and mean survival ±75 months. The recurrence rate after radical resection was 38% being 14%, 30%, 78% and 100% in Dukes classes A, B, C and D. The cumulative 5-year survival of men, 45%, was significantly worse than that of women, 73%, and this phenomenon was closely related to more distended lymphatic and venous invasion of cancer in men. Kaplan–Meier estimates showed that gender, Dukes staging, grade of tumour, lymphatic invasion, the number of lymph nodes with metastases, venous invasion and size of tumour were significant predictors of survival, but in Cox regression model, only venous invasion was the independent prognostic factor of survival.
Young men with colorectal cancer in Northern Finland have poorer prognosis than women. Venous invasion is an independent predictor of survival.
KeywordsColorectal cancer Young age Predisposing conditions Pathology Survival
- 1.Institute for Statistical and Epidemiological Cancer Research (2004) Finnish Cancer Registry—Cancer incidence in Finland. Institute for Statistical and Epidemiological Cancer Research, HelsinkiGoogle Scholar
- 10.Jass JR, Sobin LH (1989) Histologic typing of intestinal tumours. World Health Organisation. International classification of tumours, 2nd edn. Springer, HeidelbergGoogle Scholar
- 26.Koopman TJ, Cats A, Rodenburg CA, Creemers GJ, Scharma JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijktra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (2009) Chemotherapy, bevacitzumab, and cetuximab in metastatic colorecla cancer. N Engl J Med 360:563–572CrossRefPubMedGoogle Scholar
- 28.Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessadroni P, Giustini L, Silva RR, Falcone A, D’Emidio S, Fedeli SL (2009) Mucous histology predicts for poor response related overall survival of patients with colorectal cancer and treated with first-line oxaliplatin-and/or irinotecan-based chemotherapy. Br J Cancer 100:881–887CrossRefPubMedGoogle Scholar